Live Breaking News & Updates on Translational Research In Oncology

Stay updated with breaking news from Translational research in oncology. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Drug cuts risk of breast cancer recurrence for some early-stage patients, trial shows

A drug used in people in the early stage of the most common kind of breast cancer – HR+/HER2- breast cancer – significantly reduced the risk of the cancer returning ....

United States , Anupama Goel , Shreeram Aradhye , Sara Tolaney , Dennisj Slamon , Alberto Montero , Jonsson Comprehensive Cancer Center , Discovery Company , Uh Seidman Cancer Center , Translational Research In Oncology , Drug Administration , Dana Farber Cancer Institute , Warner Bros , American Society Of Clinical Oncology , Mount Sinai Tisch Cancer Center , Case Western Reserve University School Of Medicine , Cable News Network Inc , American Society , Clinical Oncology , Comprehensive Cancer Center , Cancer Center , Case Western Reserve University School , News Network ,

Drug cuts risk of breast cancer recurrence for some early-stage patients, trial shows

(CNN) — A drug used in people in the early stage of the most common kind of breast cancer – HR+/HER2- breast cancer – significantly reduced the risk of the ....

United States , Sara Tolaney , Alberto Montero , Shreeram Aradhye , Dennisj Slamon , Anupama Goel , Translational Research In Oncology , Drug Administration , Jonsson Comprehensive Cancer Center , Warner Bros , Case Western Reserve University School Of Medicine , Dana Farber Cancer Institute , Discovery Company , American Society Of Clinical Oncology , Mount Sinai Tisch Cancer Center , Cable News Network Inc , Uh Seidman Cancer Center , American Society , Clinical Oncology , Comprehensive Cancer Center , Cancer Center , Case Western Reserve University School , News Network ,

Novartis Pharma AG: Novartis Kisqali® significantly reduced the risk of recurrence by 25% across a broad population of patients with early breast cancer; clinically meaningful benefit was consistent across subgroups

Kisqali is the first and only CDK4/6 inhibitor to demonstrate a consistent, clinically meaningful benefit across a broad population of patients with HR+/HER2- early breast cancer, regardless of disease ....

United States , San Antonio , France General , Comunidad Autonoma De Cataluna , Samir Shah , Nicole Zinsli Somm , Richard Jarvis , Isabella Zinck , Satoshi Sugimoto , Dennisj Slamon , Shreeram Aradhye , Marlena Abdinoor , Julie Masow , Parag Mahanti , Fran Visco , Mary Carmichael , Michael Meo , Sloan Simpson , Jonsson Comprehensive Cancer Center , National Breast Cancer Coalition , American Society Of Clinical Oncology , American Cancer Society , Steering Committee , European Commission , Astex Pharmaceuticals , American Society Of Clinical Oncology Annual Meeting ,

Ribociclib Lowers Risk of Disease Recurrence by 25% for Early Breast Cancer

Ribociclib (Kisqali) demonstrated a 26% risk reduction in distant disease-free survival and a 28% risk reduction in recurrence-free survival in patients with HR+/HER2- early breast cancer. ....

United States , Shreeram Aradhye , Dennisj Slamon , Ribociclib Kisqali , Translational Research In Oncology , American Society Of Clinical Oncology Annual Meeting , Clinical Translational Research , Global Drug Development , Clinical Oncology Annual , Translational Research , California Los Angeles , Jonsson Comprehensive Cancer Center ,